5 assets in Malignancy In Giant Cell Tumor Of Bone

Therapeutic assets addressing Malignancy In Giant Cell Tumor Of Bone, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Malignancy In Giant Cell Tumor Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Fludarabine Malignancy In Giant Cell Tumor Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Malignancy In Giant Cell Tumor Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Lifileucel Malignancy In Giant Cell Tumor Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Malignancy In Giant Cell Tumor Of Bone	M.D. Anderson Cancer Center	P2	CCC (53)